Advances in the Application of Precision Medicine-based Approach for Guiding the Diagnosis and Treatment of Chronic Hepatitis C

doi:10.3969/j.issn.1007-9572.2018.00.078

Abstract

Abstract: Hepatitis C（HCV），with strong infectiousness and highly variable viral genome，has been widely spread，causing global public health problems.Precision medicine，based on individualized treatment，is a hot spot attracting the attention of both the public and the academic realm.A large number of medical frontier technologies are used to develop the precision medical model for the prevention and treatment of specific patients.This paper reviews the impact of HCV genotyping on the diagnosis of hepatitis C，achievements in genomics，proteomics，pharmaco metabonomics and other high-throughput proteomic technologies，biomarkers and potential therapeutic targets related to HCV diagnosis and treatment，as well as the prospect of precision medicine-based approach used for the guide of chronic HCV diagnosis，treatment and prognosis assessment.

Key words: Precision medicine, Hepatitis C, Genomics, Proteomics, Metabolomics, Biomarker

摘要： 丙型肝炎传染性强、流行面广，病毒基因组高度变异，是全球性公共卫生难题之一。精准医疗是以个体化治疗为基础应用大量医学前沿技术针对特定患者制定相应的疾病预防与治疗的医疗模式，是目前公众和学术关注的热点。本文综述了丙型肝炎病毒基因分型在丙型肝炎分型诊断中的作用，丙型肝炎在基因组学、蛋白质组学、药物代谢组学等高通量组学技术方面的发展，丙型肝炎生物标志物及潜在治疗靶点等研究成果，探讨精准医学理念在丙型肝炎诊断、治疗及预后中的应用前景。

关键词: 精准医学, 丙型肝炎, 基因组学, 蛋白质组学, 代谢组学, 生物标志物

LU Ming-zi,ZHU Wei,ZHANG Xiao-kun, et al. Advances in the Application of Precision Medicine-based Approach for Guiding the Diagnosis and Treatment of Chronic Hepatitis C[J]. Chinese General Practice, 2018, 21(27): 3393-3396. DOI: 10.3969/j.issn.1007-9572.2018.00.078.
卢明子,朱伟,张晓琨等. 精准医学理念在丙型肝炎诊治中的应用进展[J]. 中国全科医学, 2018, 21(27): 3393-3396. DOI: 10.3969/j.issn.1007-9572.2018.00.078.

References

［1］National Research Council（US）Committee.Toward precision medicine：building a knowledge network for biomedical research and a new taxonomy of disease［M］.Washington DC：National Academies Press，2011.3395
［2］焦怡琳，王吉春，张群，等.中国在精准医学领域面临的机遇与挑战［J］.中国公共卫生管理，2015，31（5）：601-603.DOI：10.19568/j.cnki.23-1318.2015.05.001.3395
JIAO Y L，WANG J C，ZHANG Q，et al.Opportunities and challenges in field of precision medicine in China［J］.Zhongguo Gonggong Weisheng Guanli，2015，31（5）：601-603.DOI：10.19568/j.cnki.23-1318.2015.05.001.3395
［3］VENEGAS M，BRAHM J，VILLANUEVA R A.Genomic determinants of hepatitis C virus antiviral therapy outcomes：toward individualized treatment［J］.Ann Hepatol，2012，11（6）：827-837.3395
［4］MOHD HANAFIAH K，GROEGER J，FLAXMAN A D，et al. Global Epidemiology of hepatitis C virus infection：new estimates of age-specific antibody to HCV seroprevalence［J］.Hepatology，2013，57（4）：1333-1342.DOI：10.1002/hep.26141.3395
［5］李伟琴，袁致海，徐光华，等.丙型肝炎基因分型进展及其临床意义［J］.世界华人消化杂志，2009，17（6）：589-593.DOI：10.3969/j.issn.1009-3079.2009.06.010.3395
LI W Q，YUAN Z H，XU G H，et al.Progress in hepatitis C genotyping and its clinical significance［J］.World Chinese Journal of Digestology，2009，17（6）：589-593.DOI：10.3969/j.issn.1009-3079.2009.06.010.3395
［6］MESSINA J P，HUMPHREYS I，FLAXMAN A，et al.Global distribution and prevalence of hepatitis C virus genotypes［J］.Hepatology，2015，61（1）：77-87.DOI：10.1002/hep.27259.3395
［7］THRIFT A P，EL-SERAG H B，KANWAL F.Global epidemiology and burden of HCV infection and HCV-related disease［J］.Nat Rev Gastroenterol Hepatol，2017，14（2）：123-132.DOI：10.1038/nrgastro.2016.176.3395
［8］中华医学会肝病学分会，中华医学会感染病学分会.丙型肝炎防治指南（ 2015 年更新版）［J］.临床肝胆病杂志，2015，31（12）：1961-1979.DOI：10.3969/j.issn.1674-7380.2015.03.002.3395
Chinese Society of Hepatology，Chinese Medical Association，Chinese Society of Infectious Diseases，Chinese Medical Association.Guide for hepatitis C prevention（2015）［J］.Chinese Journal of Clinical Hepatology，2015，31（12）：1961-1979.DOI：10.3969/j.issn.1674-7380.2015.03.002.3395
［9］GOWER E，ESTES C，BLACH S，et al.Global epidemiology and genotype distribution of the hepatitis C virus infection［J］.Journal of Hepatology，2014，61（1 Suppl）：S45-57.DOI：10.1016/j.jhep.2014.07.027.3395
［10］RAIMONDI S，BRUNO S，MONDELLI M U，et al.Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development：a meta-analysis［J］.J Hepatol，2009，50（6）：1142-1154.DOI：10.1016/j.jhep.2009.01.019.3395
［11］PROBST A，DANG T，BOCHUD M，et al.Role of hepatitis C virus genotype 3 in liver fibrosis progression - a systematic review and meta-analysis［J］.J Viral Hepat，2011，18（11）：745-759.DOI：10.1111/j.1365-2893.2011.01481.x.3395
［12］BOCHUD P Y，CAI T，OVERBECK K，et al.Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C［J］.J Hepatol，2009，51（4）：655-666.DOI：10.1016/j.jhep.2009.05.016.3395
［13］CUYPERS L，CECCHERINI-SILBERSTEIN F，VAN LAETHEM K，et al.Impact of HCV genotype on treatment regimens and drug resistance：a snapshot in time［J］.Rev Med Virol，2016，26（6）：408-434.DOI：10.1002/rmv.1895.3395
［14］GE D，FELLAY J，THOMPSON A J，et al.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance［J］.Nature，2009，461（7262）：399-401.DOI：10.1038/nature08309.3395
［15］THOMAS D L，THIO C L，MARTIN M P，et al.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus［J］.Nature，2009，461（7265）：798-801.DOI：10.1038/nature08463.3395
［16］SUPPIAH V，MOLDOVAN M，AHLENSTIEL G，et al.IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy［J］.Nat Genet，2009，41（10）：1100-1104.DOI：10.1038/ng.447.3396
［17］AKUTA N，SUZUKI F，HIRAKAWA M，et al.Amino acid substitution in hepatitis C virus coreregion and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin［J］.Hepatology，2010，52（2）：421-429.DOI：10.1002/hep.23690.3396
［18］POORDAD F，BRONOWICKI J P，GORDON S C，et al.IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir（Boc）combination therapy［J］.J Hepatol，2011，54（5）：S6.DOI：10.1016/S0016-5085（11）63904-8.3396
［19］DIAMOND D L，SYDER A J，JACOBS J M，et al.Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics［J］.PLoS Pathog，2010，6（1）：e1000719.DOI：10.1371/journal.ppat.1000719.3396
［20］GOUTHAMCHANDRA K，KUMAR A，SHWETHA S，et al.Serum proteomics of hepatitis C virus infection reveals retinol-binding protein 4 as a novel regulator［J］.J Gen Virol，2014，95（Pt 8）：1654-1667.DOI：10.1099/vir.0.062430-0.3396
［21］LEE I N，CHEN C H，SHEU J C，et al.Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach［J］.Proteomics，2006，6（9）：2865-2873.DOI：10.1002/pmic.200500488.3396
［22］WHITE I R，PATEL K，SYMONDS W T，et al.Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection［J］.J Transl Med，2007，5：33.DOI：10.1186/1479-5876-5-33.3396
［23］PARADIS V，ASSELAH T，DARGERE D，et al.Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin［J］.Gastroenterology，2006，130（7）：2189-2197.DOI：10.1053/j.gastro.2006.02.059.3396
［24］PATEL K，LUCAS J E，THOMPSON J W，et al.High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients［J］.Hepatology，2011，53（6）：1809-1818.DOI：10.1002/hep.24284.3396
［25］ILSE D P，NOMATHAMSANQA P S.The use of metabolomics as a tool to investigate hepatitis C［J］.Metabolomics，2013，9（2）：497-505.DOI：10.1007/s11306-012-0467-8.3396
［26］SEMMO N，WEBER T，IDLE J R，et al.Metabolomics reveals that aldose reductase activity due to AKR1B10 is upregulated in hepatitis C virus infection［J］.J Viral Hepat，2015，22（7）：617-624.DOI：10.1111/jvh.12376.3396
［27］GODOY M M，LOPES E P，SILVA R O，et al.Hepatitis C virus infection diagnosis using metabonomics［J］.J Viral Hepat，2010，17（12）：854-858.DOI：10.1111/j.1365-2893.2009.01252.x.3396
［28］SAITO T，SUGIMOTO M，IGARASHI K，et al.Dynamics of serum metabolites in patients with chronic hepatitis C receiving pegylated interferon plus ribavirin：a meta bolomics analysis［J］.Metabolism，2013，62（11）：1577-1586.DOI：10.1016/j.metabol.2013.07.002.3396
［29］JOPLING C L，YI M，LANCASTER A M，et al.Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA［J］.Science，2005，309（5740）：1577-1581.DOI：10.1126/science.1113329.3396
［30］JANGRA R K，YI M，LEMON S M.Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122［J］.J Virol，2010，84（13）：6615-6625.DOI：10.1128/JVI.00417-10.3396
［31］SU T H，LIU C H，LIU C J，et al.Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C［J］.Proc Natl Acad Sci U S A，2013，110（19）：7844-7849.DOI：10.1073/pnas.1306138110.3396
［32］SARASIN-FILIPOWICZ M，KROL J，MARKIEWICZ I.Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy［J］.Nat Med，2009，15（1）：31-33.DOI：10.1038/nm.1902.3396
［33］LANFORD R E，HILDEBRANDT-ERIKSEN E S，PETRI A，et al.Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection［J］.Science，2010，327（5962）：198-201.DOI：10.1126/science.1178178.3396
［34］SHRIVASTAVA S，PETRONE J，STEELE R.Up-regulation of circulating miR-20a is correlated with hepatitis C virus mediated liver disease progression［J］.Hepatology，2013，58（3）：863-871.DOI：10.1002/hep.26296.3396
［35］PEDERSEN I M，CHENG G，WIELAND S，et al.Interferon modulation of cellular microRNAs as an antiviral mechanism［J］.Nature，2007，449（7164）：919-922.DOI：10.1038/nature06205.3396
［36］BANDYOPADHYAY S，FRIEDMAN R C，MARQUEZ R T，et al.Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29：miR-29overexpression reduces hepatitis C viral abundance in culture［J］.J Infect Dis，2011，203（12）：1753-1762.DOI：10.1093/infdis/jir186.3396
［37］BHANJA CHOWDHURY J，SHRIVASTAVA S，STEELE R，et al.Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A［J］.J Virol，2012，86（18）：10221-10225.DOI：10.1128/JVI.00882-12.3396
［38］SHIRASAKI T，HONDA M，SHIMAKAMI T，et al.MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells［J］.J Virol，2013，87（9）：5270-5286.DOI：10.1128/JVI.03022-12.3396
［39］CHENG J C，YEH Y J，TSENG C P，et al.Let-7b is a novel regulator of hepatitis C virus replication［J］.Cell Mol Life Sci，2012，69（15）：2621-2633.DOI：10.1007/s00018-012-0940-6.3396

[1]	ZHANG Kexing, ZHANG Bo, WU Qiong, ZHU Shanshan, WANG Di, ZHANG Chunnan. Research on the Mechanism of Action of Simiao Yongan Decoction in the Treatment of Diabetic Foot Based on Metabolomics [J]. Chinese General Practice, 2025, 28(30): 3796-3805.
[2]	ZHANG Hongshi, QU Zihan, SUN Xuefeng, WANG Yufeng, CONG Deyu, ZHANG Ye. Effect of Abdominal Massage on Hypothalamus of Insomnia Rats Based on Proteomics [J]. Chinese General Practice, 2025, 28(27): 3399-3409.
[3]	WANG Shuang, WU Shufa, LING Yao, TAN Xiwei, CAO Rudai, ZENG Huiting, KONG Danli, DING Yuanlin, YU Haibing. Metabolomics Based Mediating Role of Non-lipid Metabolites in the Relationship between Obesity and Diabetic Retinopathy: a Mendelian Randomization Study [J]. Chinese General Practice, 2025, 28(21): 2625-2634.
[4]	YUAN Xiaorui, TAN Yanlin, FU Chun. Construction of the Predictive Model for Lymph Node Metastasis in Patients with Epithelial Ovarian Cancer: Based on ¹⁸F-FDG PET/CT Radiomics Technology [J]. Chinese General Practice, 2025, 28(12): 1465-1472.
[5]	ZHANG Yushuang, WU Zhongbing, HUANG Ming, JIA Lei, GAO Shuang, ZHAO Weipeng, LI Jing. Study on Metabolic Characteristics in Esophageal Squamous Cell Carcinoma Patients with TCM Differentiation of Deficiency of Fluid and Blood Based on Non Target Metabolomics [J]. Chinese General Practice, 2025, 28(12): 1513-1519.
[6]	MA Xiaoxuan, WANG Rongqi. Research Progress in Metabolomics for HCC Diagnosis and Treatment [J]. Chinese General Practice, 2025, 28(08): 1017-1022.
[7]	HUANG Xiangping, WU Ling, TAN Chaochao. Serum Metabolomic Study on the Difference between Mild and Severe Acute Pancreatitis Based on Liquid Chromatography-tandem Mass Spectrometry [J]. Chinese General Practice, 2023, 26(09): 1118-1124.
[8]	MIAO Xueyi, DING Lingyu, LU Jinling, HU Jieman, ZHU Hanfei, CHEN Li, XU Xinyi, XU Qin. Preoperative Frailty and Postoperative Adverse Outcomes among Elderly Patients with Gastric Cancer [J]. Chinese General Practice, 2023, 26(08): 980-988.
[9]	Xiucheng YANG, Zhangping HONG, Qing LIU, Yong HU, Jie LI, Xinglin YANG. Status and Influencing Factors of HIV/AIDS Patients Co-infected with Hepatitis C Virus in Guizhou [J]. Chinese General Practice, 2022, 25(28): 3531-3536.
[10]	Huanhuan LIU, Jing GAO, Kaiqi SU, Xiaodong FENG. Advances in the Mechanism of Enriched Environment Improving Chronic Cerebral Hypoperfusion-induced Cognitive Impairment [J]. Chinese General Practice, 2022, 25(23): 2903-2909.
[11]	Jiehong KANG, Xiangyun CHANG, Yurong ZHU, Tao BA, Yuan SUN. Association of Cyclic RNAs with the Risk of Type 2 Diabetes Mellitus in Han Chinese [J]. Chinese General Practice, 2022, 25(15): 1863-1868.
[12]	WU Ruijian, HUANG Yuge, LUO Lianxiang. Metabolomics in Childhood Asthma [J]. Chinese General Practice, 2022, 25(08): 1014-1020.
[13]	LI Guangxu，LI Yuanlong，LU Jun，SUN Weiwei. Diagnostic Value of Next-generation Sequencing of Cerebrospinal Fluid for Viral Encephalitis：Report of 3 Cases　 [J]. Chinese General Practice, 2021, 24(6): 744-747.
[14]	YAO Lihui，MENG Xiaojing，WANG Zhongxian，CHEN Yuanyuan，CHENG Peng，SHI Li，LI Jingwei，SU Hong，ZHANG Xulai. Changes of Gut Microbial Metabolism and Blood Lipid Level on Schizophrenia at Different Stages　 [J]. Chinese General Practice, 2021, 24(26): 3295-3301.
[15]	LIANG Wenyan，MA Aixia. Clinical Application of Direct-acting Antivirals in Hepatitis C Patients　 [J]. Chinese General Practice, 2020, 23(29): 3661-3666.